Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage

View ORCID ProfileFrederic Grabowski, Grzegorz Preibisch, View ORCID ProfileMarek Kochańczyk, View ORCID ProfileTomasz Lipniacki
doi: https://doi.org/10.1101/2020.12.28.20248906
Frederic Grabowski
1Institute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Frederic Grabowski
Grzegorz Preibisch
2Inter-Faculty Individual Studies in Mathematics and Natural Sciences, The MISMaP College, University of Warsaw, 02-087 Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marek Kochańczyk
1Institute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marek Kochańczyk
Tomasz Lipniacki
1Institute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, Poland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomasz Lipniacki
  • For correspondence: tlipnia@ippt.pan.pl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Article Information

doi 
https://doi.org/10.1101/2020.12.28.20248906
History 
  • January 4, 2021.

Article Versions

  • You are currently viewing Version 1 of this article (January 4, 2021 - 05:06).
  • View Version 2, the most recent version of this article.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Frederic Grabowski1,
  2. Grzegorz Preibisch2,
  3. Marek Kochańczyk1 and
  4. Tomasz Lipniacki1,*
  1. 1Institute of Fundamental Technological Research, Polish Academy of Sciences, 02-106 Warsaw, Poland
  2. 2Inter-Faculty Individual Studies in Mathematics and Natural Sciences, The MISMaP College, University of Warsaw, 02-087 Warsaw, Poland
  1. ↵*Corresponding author’s e-mail: tlipnia{at}ippt.pan.pl
Back to top
PreviousNext
Posted January 04, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage
Frederic Grabowski, Grzegorz Preibisch, Marek Kochańczyk, Tomasz Lipniacki
medRxiv 2020.12.28.20248906; doi: https://doi.org/10.1101/2020.12.28.20248906
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Variant Under Investigation 202012/01 has more than twofold replicative advantage
Frederic Grabowski, Grzegorz Preibisch, Marek Kochańczyk, Tomasz Lipniacki
medRxiv 2020.12.28.20248906; doi: https://doi.org/10.1101/2020.12.28.20248906

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3825)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)